Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 2 , Pages 382-390 , April 2010

Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas

  • Darya Alizadeh, MS

      Affiliations

    • Division of Neurosurgery, City of Hope National Cancer Center, Duarte, California, USA
    • ,
  • Leying Zhang, PhD

      Affiliations

    • Division of Neurosurgery, City of Hope National Cancer Center, Duarte, California, USA
    • ,
  • Jungyeon- Hwang, PhD

      Affiliations

    • Calando Pharmaceuticals, Pasadena, California, USA
    • ,
  • Thomas Schluep, ScD

      Affiliations

    • Calando Pharmaceuticals, Pasadena, California, USA
    • ,
  • Behnam Badie, MD

      Affiliations

    • Division of Neurosurgery, City of Hope National Cancer Center, Duarte, California, USA
    • Corresponding Author InformationCorresponding author:

Received 2 February 2009 ,Accepted 1 October 2009.

References 

  1. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25:2295–2305
  2. Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24:1733–1744
  3. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23:35–58
  4. Jain KK. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev Neurother. 2007;7:363–372
  5. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615–1626
  6. Reimold I, Domke D, Bender J, Seyfried CA, Radunz HE, Fricker G. Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur J Pharm Biopharm. 2008;70:627–632
  7. Galea I, Bechmann I, Perry VH. What is immune privilege (not)?. Trends Immunol. 2007;28:12–18
  8. Djukic M. Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain. 2006;129:2394–2403
  9. Badie B, Schartner JM. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery. 2000;46:957–961discussion 61-2
  10. Roggendorf W, Strupp S, Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 1996;92:288–293
  11. Shinonaga M, Chang CC, Suzuki N, Sato M, Kuwabara T. Immunohistological evaluation of macrophage infiltrates in brain tumors. Correlation with peritumoral edema. J Neurosurg. 1988;68:259–265
  12. Streit WJ. Cellular immune response in brain tumors. Neuropathol Appl Neurobiol. 1994;20:205–206
  13. Hussain SF, Yang D, Suki D, Grimm E, Heimberger A. Innate immune functions of microglia isolated from human glioma patients. J Transl Med. 2006;4:15
  14. Nickles D, Abschuetz A, Zimmer H, Kees T, Geibig R, Spiess E, et al. End-stage dying glioma cells are engulfed by mouse microglia with a strain-dependent efficacy. J Neuroimmunol. 2008;197:10–20
  15. Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol. 2006;57:654–662
  16. VanHandel M, Alizadeh D, Zhang L, Kateb B, Bronikowski M, Manohara H, et al. Selective uptake of multi-walled carbon nanotubes by tumor macrophages in a murine glioma model. J Neuroimmunol. 2009;208:3–9
  17. Schluep T, Gunawan P, Ma L, Jensen GS, J.D. , S.H. , et al. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res. 2009;15(1):181–189
  18. Badie B, Bartley B, Schartner J. Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas. J Neuroimmunol. 2002;133:39–45
  19. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649–1659
  20. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006;12:1606–1614
  21. Watters JJ, Schartner JM, Badie B. Microglia function in brain tumors. J Neurosci Res. 2005;81:447–455
  22. Galarneau H, Villeneuve J, Gowing G, Julien JP, Vallieres L. Increased glioma growth in mice depleted of macrophages. Cancer Res. 2007;67:8874–8881
  23. Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia. 2005;51(4):279–285
  24. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117:1155–1166
  25. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–266
  26. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–612
  27. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol. 2003;21:807–839
  28. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–727
  29. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216:15–24
  30. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015–3024
  31. Nishie A, Ono M, Shono T, Fukushi J, Otsubo M, Onoue H, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999;5:1107–1113
  32. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, et al. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion—an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene. 2008;27:918–930
  33. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology. 1995;197:533–538
  34. Jackson H, Muhammad O, Daneshvar H, Nelms J, Popescu A, Vogelbaum MA, et al. Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery. 2007;60:524–529discussion 9-30
  35. Trehin R, Figueiredo JL, Pittet MJ, Weissleder R, Josephson L, Mahmood U. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia. 2006;8:302–311
  36. Carpentier AF, Tibi A, Richard M, Capelle L, Laigle-Donadey F, Behin A, et al. Local treatment with an immunostimulatory CpG-oligonucleotide in patients with recurrent glioblastoma: results of a phase I trial. In: Presented at: Second Quadrennial Meeting of the World Federation of Neuro-Oncology. May 5–8 2005;Edinburgh, UK
  37. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007;67:9630–9636
  38. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol. 2008;20:228–233
  39. Yen Y, Synold T, Schluep T, Hwang J, Oliver M, Davis ME. First-in-human phase I trial of a cyclodextrin-containing polymer-camptothecin nanoparticle in patients with solid tumors. J Clin Oncol. 2007;25(18S):14078
  40. Briegert M, Kaina B. Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res. 2007;67:26–31
  41. Davoust N, Vuaillat C, Androdias G, Nataf S. From bone marrow to microglia: barriers and avenues. Trends Immunol. 2008;29:227–234
  42. Valable S, Barbier EL, Bernaudin M, Roussel S, Segebarth C, Petit E, et al. In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma. NeuroImage. 2008;40:973–983

 The senior author owns stocks in Arrowhead Research Inc, which is a part owner of Calando Pharmaceuticals.

 This work was supported by American Cancer Society Research Scholar Grant (RSG-03-142-01-CNE), the James S. McConnell Foundation, and Insert Therapeutics (to B. Badie). The City of Hope Flow Cytometry Core was equipped in part through funding provided by ONR N00014-02-1 0958, DOD 1435-04-03GT-73134, and NSF DBI-9970143.

PII: S1549-9634(09)00189-0

doi: 10.1016/j.nano.2009.10.001

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 2 , Pages 382-390 , April 2010

Article Tools

* Image Usage & Resolution